Concepedia

Post-natalizumab disease reactivation in multiple sclerosis: systematic review and meta-analysis

Luca Prosperini, Revere P. Kinkel, Augusto Miravalle, Pietro Iaffaldano, Simone Fantaccini

Therapeutic Advances in Neurological Disorders · 2019 · 95 citations · 57 references

DOIFull text

Open access

Abstract

Results from the present review and meta-analysis can help to profile patients who are at greater risk of post-NTZ disease reactivation. However, potential reporting bias and variability in selected studies should be taken into account when interpreting our data.

References

57

Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement

David Moher, A. Liberati, Jennifer Tetzlaff et al. · BMJ · 2009 · 82.3K citations · Full text

Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement

David Moher, Alessandro Liberati, Jennifer Tetzlaff et al. · PLoS Medicine · 2009 · 61.5K citations · Full text

, , +21

A Randomized, Placebo-Controlled Trial of Natalizumab for Relapsing Multiple Sclerosis

Chris H. Polman, Paul O’Connor, Eva Havrdová et al. · New England Journal of Medicine · 2006 · 3.3K citations · Full text

Rate of Pregnancy-Related Relapse in Multiple Sclerosis

Christian Confavreux, Michael Hutchinson, Martine Hours et al. · New England Journal of Medicine · 1998 · 1.5K citations · Full text

Natalizumab plus Interferon Beta-1a for Relapsing Multiple Sclerosis

Richard A. Rudick, William H. Stuart, Peter A. Calabresi et al. · New England Journal of Medicine · 2006 · 1.3K citations · Full text